India’s Drug giant Glenmark Pharmaceuticals announced the launch of antiviral drug Favipiravir, with the name FabiFlu to treat the patients with mild to moderate Covid-19. FabiFlu is the first oral Favipiravir-approved medicine in India for the treatment of Coronavirus.
Each tablet of FabiFlu would cost about Rs 103. The medicine will be made available as a 200mg tablet at MRP of Rs 3500 for a strip of 34 tablets. The FabiFlu is a strictly prescription-based medication with a recommended dose of 1800mg twice on day one and 800 mg twice from day 2 to day 14. The drug will soon be available at hospitals and retail selling stores. The Drug firm received manufacturing and marketing approval from the DCGI (Drugs Controller General of India) n Saturday.
Favipiravir can be used for patients infected with COVID-19 with co-morbid conditions and with mild to moderate coronavirus symptoms and the drug is expected to reduce viral load within the first four days of usage. Favipiravir is proved to be improving up to 88 percent COVID-19 cases.
This post was last modified on 21 June 2020 9:15 am
The Sandhya theatre episode is drawing largely polarised responses from the public and also political…
The Telugu film industry is abuzz with developments following the unfortunate Sandhya Theater incident. Allu…